Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4538-41. doi: 10.1016/j.bmcl.2009.07.009. Epub 2009 Jul 9.

Abstract

Aryl diketoacids have been identified as the first SARS-CoV NTPase/helicase inhibitors with a distinct pharmacophore featuring an arylmethyl group attached to a diketoacid. In order to search for the pharmacophore space around the diketoacid core, three classes of dihydroxychromone derivatives were prepared. Based on SAR study, an extended feature of the pharmacophore model of SARS-CoV NTPase/helicase was proposed which is constituted of a diketoacid core, a hydrophobic arylmethyl substituent, and a free catechol unit.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / chemical synthesis
  • Antiviral Agents / chemistry*
  • Antiviral Agents / pharmacology
  • Catechols / chemistry
  • Chromones / chemical synthesis
  • Chromones / chemistry*
  • Chromones / pharmacology
  • DNA Helicases / antagonists & inhibitors*
  • DNA Helicases / metabolism
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / pharmacology
  • Severe acute respiratory syndrome-related coronavirus / enzymology*
  • Structure-Activity Relationship

Substances

  • Antiviral Agents
  • Catechols
  • Chromones
  • Enzyme Inhibitors
  • DNA Helicases
  • catechol